IP Verse

Manipulation Of Immunoglobulin Gene Diversity And Multi-Antibody Therapeutics - EP2757875

The patent EP2757875 was granted to Kymab on Mar 22, 2023. The application was originally filed on Sep 18, 2012 under application number EP12762378A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2757875

KYMAB
Application Number
EP12762378A
Filing Date
Sep 18, 2012
Status
Patent Maintained As Amended
Feb 17, 2023
Grant Date
Mar 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

REGENERON PHARMACEUTICALSAug 27, 2018J A KEMPADMISSIBLE

Patent Citations (53) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2010GB51122-
DESCRIPTIONEP0937140
DESCRIPTIONEP1034260
DESCRIPTIONEP1204740
DESCRIPTIONEP1399559
DESCRIPTIONEP1523496
DESCRIPTIONUS5859301
DESCRIPTIONUS5939598
DESCRIPTIONUS6130364
DESCRIPTIONUS6586251
DESCRIPTIONUS6673986
DESCRIPTIONUS7501552
DESCRIPTIONWO02066630
DESCRIPTIONWO2004041862
DESCRIPTIONWO2004041863
DESCRIPTIONWO2009076464
DESCRIPTIONWO2009143472
DESCRIPTIONWO2010039900
DESCRIPTIONWO2010109165
DESCRIPTIONWO2011004192
DESCRIPTIONWO2011097603
DESCRIPTIONWO9404678
EXAMINATIONWO2011097603
INTERNATIONAL-SEARCH-REPORTWO02053596
INTERNATIONAL-SEARCH-REPORTWO2011004192
OPPOSITIONUS5545806
OPPOSITIONUS6596541
OPPOSITIONWO02053596
OPPOSITIONWO02066630
OPPOSITIONWO2007117410
OPPOSITIONWO2008054606
OPPOSITIONWO2009018411
OPPOSITIONWO2010039900
OPPOSITIONWO2010077854
OPPOSITIONWO2011004192
OPPOSITIONWO2011097603
OPPOSITIONWO2011158009
OPPOSITIONWO2011163311
OPPOSITIONWO2011163314
OPPOSITIONWO2012018764
OPPOSITIONWO2013059230
OPPOSITIONWO2013130981
OPPOSITIONWO9824893
OTHERWO02066630
OTHERWO2008054606
OTHERWO2010039900
OTHERWO2011004192
OTHERWO2011097603
OTHERWO2011163311
OTHERWO2011163314
OTHERWO2012018764
OTHERWO2013059230
OTHERWO9824893

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- BRADSHAW et al., "Chapter 5 Antibody-Antigen Recognition and Conformational Changes", BRADSHAW et al., Bradshaw, Handbook of Cell Signalling, (20100000), page 33, XP055516785-
OPPOSITION- BRUGGEMANN et al., "Human antibody expression in transgenic mice", Achivum Imunologiae et Therapiae Experimentalis, (20010000), vol. 49, pages 203 - 208, XP009039754-
OPPOSITION- FEENEY, A. J., "Genetic and epigenetic control of V gene rearrangement frequency", In V(D)J Recombination, (20090000), vol. 650, pages 73 - 81, XP009169605-
OPPOSITION- ICHIHARA et al., "Organization of human immunoglobulin heavy chain diversity gene loci.", EMBO Journal, (19880000), vol. 7, no. 13, pages 4141 - 4150, XP000004234-
OPPOSITION- IMGT, Database accession no. X13972-
OPPOSITION- LEFRANC et al., "Nomenclature", The Immunoglobulin Facts Book, (20010000), page 104, XP055351477-
OPPOSITION- MURPHY et al., "Chapter 4: The Generation of Lymphocyte Antigen Receptors", MURPHY et al., Murphy et al., Janeway's Immunobiology Seventh edition, (20080000), page 154-
OPPOSITION- NAGLE, "Regeneron helps make Sanofi Velocimmune to its 'weak' pipeline", InPharma, (20071203), URL: https://www.in-pharmatechnologist.com/Article/2007/12/03/Regeneron-helps-make-Sanofi-VelocImmune-to-its-weak-pipeline, XP055516757-
OPPOSITION- NICHOLSON et al., "Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes", J Immunol, (19990000), vol. 163, no. 12, pages 6898 - 6906, XP002974255-
OPPOSITION- ROSNER et al., "Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes", Immunology, (20010000), vol. 103, pages 179 - 187, XP055516887-
OPPOSITION- YU et al., "Differential usage of V(H) gene segments is mediated by cis elements", J Immunol, (19980000), vol. 161, no. 7, pages 3444 - 3454, XP002697039-
OPPOSITION- GALLO et al., "The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans", European Journal of Immunology, (20000000), vol. 30, pages 534 - 540, XP003035688
OPPOSITION- BRÃœGGEMANN et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus", Eur J Immunol, (19910000), vol. 21, no. 5, pages 1323 - 1326, XP000944561
OPPOSITION- ZEMLIN et al., "Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of Structures", Journal of Molecular Biology, (20030000), vol. 334, no. 4, pages 733 - 749, XP004473368
OPPOSITION- Larry I Green, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", J Immunol Methods, (19990000), vol. 231, no. 1-2, pages 11 - 23, XP004187631
OPPOSITION- MURPHY, "Veloclmmune: Immunoglobulin Variable Region Humanised Mice", Recombinant Antibodies for Immunotherapy, Cambridge University Press , New York, Cambridge University Press, New York, (20090000), pages 100 - 107, XP055343725
OPPOSITION- KLING, "Big Pharma vies for mice", Nature Biotechnology, (20070000), vol. 25, no. 6, pages 613 - 614, XP055304499
OPPOSITION- SCOTT, "Mice with a human touch", Nature Biotechnology, (20070000), vol. 25, no. 10, pages 1075 - 1077, XP055098497
OPPOSITION- LEE et al., "Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery", Nature biotechnology, (20140000), vol. 32, no. 4, pages 356 - 363, XP055131583
OPPOSITION- MENDEZ et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice", Nat Genet., (19970000), vol. 15, no. 2, pages 146 - 156, XP002918152
OPPOSITION- GREEN et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs", Nature Genetics, (19940000), vol. 7, no. 1, pages 13 - 21, XP000953045
OPPOSITION- HUANG et al., "Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120", PNAS, (20040000), vol. 101, no. 9, pages 2706 - 2711, XP002689790
OPPOSITION- SCHROEDER et al., "Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life", PNAS, (19900000), vol. 87, no. 16, pages 6146 - 6150, XP002689791
OPPOSITION- ROCK et al., "CDR3 length in antigen-specific immune receptors.", Journal of Experimental Medicine, (19940000), vol. 179, pages 323 - 328, XP000647839
OPPOSITION- NADEL et al., "Sequence of the spacer in the recombination signal sequence affects V(D)J rearrangement frequency and correlates with nonrandom Vkappa usage in vivo", J Exp Med., (19980504), vol. 187, no. 9, pages 1495 - 1503, XP002697040
OPPOSITION- ADEKAR et al., "A Natural Human IgM Antibody that Neutralizes Botulinum Neurotoxin in vivo", Hybridoma, (20080000), vol. 27, no. 2, pages 65 - 69, XP055329917
OPPOSITION- TAYLOR, "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM.", International Immunology, (19940000), vol. 6, no. 4, pages 579 - 591, XP000944310
OPPOSITION- RAAPHORST et al., "Human Ig heavy chain CDR3 regions in adult bone marrow pre-B cells display an adult phenotype of diversity: evidence for structural selection of DH amino acid sequences", International Immunology, (19970000), vol. 9, no. 10, pages 1503 - 1515, XP055409001
OPPOSITION- TAYLOR et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins", Nucleic Acids Research, (19920000), vol. 20, no. 23, pages 6287 - 6295, XP002041128
OPPOSITION- LIU et al., "Potent and Broad Anti-HIV-1 Activity Exhibited by a Glycosyl-Phosphatidylinositol-Anchored Peptide Derived from the CDR H3 of Broadly Neutralizing Antibody PG16", J. Virology, (20110000), vol. 85, no. 17, pages 8467 - 8476, XP002689792
OPPOSITION- JUNG et al., "Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus", Annu. Rev. Immunol., (20060000), vol. 24, pages 541 - 570, XP002473551
OPPOSITION- LEFRANC, "Nomenclature of the human immunoglobulin heavy (IGH) genes", Exp. Clin. Immunogenet., (20010000), vol. 18, no. 2, pages 100 - 116, XP009096782
OPPOSITION- LEFRANC, "Nomenclature of the human immunoglobulin kappa (IGK) genes", Exp. Clin. Immunogenet., (20010000), vol. 18, pages 161 - 174, XP009096781
OPPOSITION- BRINEY et al., "Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes", PLoS ONE, (20120000), vol. 7, no. 5, pages 1 - 13, XP055048579
OPPOSITION- LONBERG et al., "Human antibodies from transgenic mice", International Reviews of Immunol., (19950000), vol. 13, pages 65 - 93, XP002156616
OTHER- LEFRANC M.P., "NOMENCLATURE OF THE HUMAN IMMUNOGLOBULIN HEAVY (IGH) GENES", XPERIMENTAL AND CLINICAL IMMUNOGENETICS, (2001), vol. 18, no. 2, doi:10.1159/000049189, pages 100 - 116, XP009096782
OTHER- LEFRANC M.P., "NOMENCLATURE OF THE HUMAN IMMUNOGLOBULIN KAPPA (IGK) GENES", EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, (2001), vol. 18, no. 3, doi:10.1159/000049195, pages 161 - 174, XP009096781

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents